Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Fast versus slow disease progression in amyotrophic lateral sclerosis–clinical and genetic factors at the edges of the survival spectrum.
Neurobiol. Aging 119, 117-126 (2022)
Patients with amyotrophic lateral sclerosis (ALS) show substantial differences in disease progression and survival. However, the genetic contribution to the extremes of this spectrum remains poorly characterized. We unbiasedly selected and genotyped 102 ALS patients with very short (<15 months) and 90 with very long survival (>100 months) from the ALS registry of Ulm University using whole-exome sequencing and C9orf72 repeat expansion testing followed by a clinicogenetic correlation analysis. Clinically, groups significantly differed regarding site of disease onset, age at onset, BMI at diagnosis, disease progression rates, and diagnostic latency. We found a monogenic disease cause in 31 patients (16%) without significant differences in patients with short and long survival (19% vs. 13%; p = 0.41), but differences in the genotypic architecture. C9orf72 expansions and FUS mutations were only found in fast progressors, whereas SOD1 variants were frequent in both groups contributing 52% of all monogenic cases–33% among fast and 75% among slow variants. Our genotype-phenotype correlation may be relevant for genetic counseling, estimation of prognosis, and therapeutic decisions.
Impact Factor
Scopus SNIP
Altmetric
5.133
1.208
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Amyotrophic Lateral Sclerosis ; Disease Progression ; Exome Sequencing ; Prognostic Factors ; Sod1 ; Survival
Sprache
englisch
Veröffentlichungsjahr
2022
HGF-Berichtsjahr
2022
ISSN (print) / ISBN
0197-4580
e-ISSN
1558-1497
Zeitschrift
Neurobiology of Aging
Quellenangaben
Band: 119,
Seiten: 117-126
Verlag
Elsevier
Verlagsort
New York, NY [u.a.]
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Neurogenomics (ING)
POF Topic(s)
30205 - Bioengineering and Digital Health
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-503200-001
Förderungen
Universität Ulm
Deutsche Gesellschaft für Neurologie
Fondation Charcot
Deutsche Forschungsgemeinschaft
Boehringer Ingelheim
Teva Pharmaceutical Industries
Biogen
Deutsche Gesellschaft für Neurologie
Fondation Charcot
Deutsche Forschungsgemeinschaft
Boehringer Ingelheim
Teva Pharmaceutical Industries
Biogen
WOS ID
WOS:000890376400001
Scopus ID
85135403649
PubMed ID
35933239
Erfassungsdatum
2022-11-08